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This standard is based on NG49, NG56, CG165 and NG50. 
This standard should be read in conjunction with QS140, QS127, QS111, QS94, QS83, QS65, 
QS38, QS13 and QS11. 
Quality statements 
Statement 1 People with non-alcoholic fatty liver disease are given advice on physical activity, diet 
and alcohol. 
Statement 2 People with non-alcoholic fatty liver disease are offered regular testing for advanced 
liver fibrosis. 
Statement 3 Young people and adults with risk factors for cirrhosis are offered non-invasive testing 
for cirrhosis. 
Statement 4 Adults with cirrhosis are offered 6-monthly surveillance for hepatocellular carcinoma. 
Statement 5 Young people and adults with cirrhosis and upper gastrointestinal bleeding are given 
prophylactic intravenous antibiotics at presentation. 
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NICE has developed guidance and a quality standard on patient experience in adult NHS 
services (see the NICE Pathway on patient experience in adult NHS services), which should be 
considered alongside these quality statements. 
Other quality standards that should be considered when commissioning or providing liver 
disease services include: 
• Transition from children's to adults' services. NICE quality standard 140 
• Obesity: clinical assessment and management. NICE quality standard 127 
• Obesity in adults: prevention and lifestyle weight management programmes. NICE 
quality standard 111 
• Obesity in children and young people: prevention and lifestyle weight management 
programmes. NICE quality standard 94 
• Alcohol: preventing harmful use in the community. NICE quality standard 83 
• Hepatitis B. NICE quality standard 65 
• Acute upper gastrointestinal bleeding in adults. NICE quality standard 38 
• End of life care for adults. NICE quality standard 13 
• Alcohol-use disorders: diagnosis and management. NICE quality standard 11 
A full list of NICE quality standards is available from the quality standards topic library. 
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Quality statement 1: Advice on physical activity, 
diet and alcohol 
Quality statement 
People with non-alcoholic fatty liver disease are given advice on physical activity, diet and alcohol. 
Rationale 
Adopting a healthy lifestyle can help to reduce the rate of progression of non-alcoholic fatty liver 
disease (NAFLD). Providing lifestyle advice to people with NAFLD can encourage them to consider 
changes they can make that might help them avoid more serious liver disease. 
Quality measures 
Structure 
Evidence of local arrangements to provide advice on physical activity, diet and alcohol to people 
with NAFLD. 
Data source: Local data collection, for example, service protocols. 
Process 
a) Proportion of people with NAFLD who are given advice on physical activity. 
Numerator – the number in the denominator who are given advice on physical activity. 
Denominator – the number of people with NAFLD. 
Data source: Local data collection, for example, audit of patient health records. 
b) Proportion of people with NAFLD who are overweight or obese who are given advice on diet. 
Numerator – the number in the denominator who are given advice on diet. 
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Denominator – the number of people with NAFLD who are overweight or obese. 
Data source: Local data collection, for example, audit of patient health records. 
c) Proportion of people with NAFLD who drink alcohol who are given advice on alcohol. 
Numerator – the number in the denominator who are given advice on alcohol. 
Denominator – the number of people with NAFLD who drink alcohol. 
Data source: Local data collection, for example, audit of patient health records. 
Outcome 
a) Awareness of people with NAFLD that lifestyle changes may help them to avoid more serious 
liver disease. 
Data source: Local data collection, for example, a patient survey. 
b) Rate of disease progression among people with NAFLD. 
Data source: Local data collection, for example, audit of patient health records. 
What the quality statement means for different 
audiences 
Service providers (general practices, community healthcare providers, hospitals and specialist liver 
units) ensure that they give advice on physical activity, diet and alcohol to people with NAFLD. 
Providers ensure that their staff know where people with NAFLD can get support if they want to 
make lifestyle changes, such as lifestyle weight management programmes. 
Healthcare professionals (such as GPs, practice nurses, hepatologists, gastroenterologists and 
specialist nurses) give advice on physical activity, diet and alcohol to people with NAFLD and 
ensure that they know where they can get support to make lifestyle changes, such as lifestyle 
weight management programmes. 
Commissioners (such as clinical commissioning groups and NHS England) commission services that 
provide advice on physical activity, diet and alcohol to people with NAFLD. Commissioners ensure 
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that information is available to healthcare professionals on the support available locally to help 
people with NAFLD to make lifestyle changes, such as lifestyle weight management programmes. 
People with non-alcoholic fatty liver disease, and their parents or carers if appropriate, are given 
advice on diet (if they need to lose weight), physical activity and alcohol consumption (if they drink 
alcohol), and are told where they can get support to make lifestyle changes. Following this advice 
can help to improve non-alcoholic fatty liver disease or stop it from getting worse. 
Source guidance 
Non-alcoholic fatty liver disease (NAFLD): assessment and management. NICE guideline NG49 
(2016), recommendations 1.2.12, 1.2.13 and 1.2.16 
Definitions of terms used in this quality statement 
Advice on physical activity, diet and alcohol 
People diagnosed with NAFLD should: 
• be offered advice on physical activity and diet if they are overweight or obese, in line with 
NICE's guidelines on obesity and preventing excess weight gain 
• be advised that there is some evidence that exercise reduces liver fat content 
• be advised that, if they drink alcohol, it is important to stay within the government's 
recommended limits for alcohol consumption. 
[NICE's guideline on non-alcoholic fatty liver disease, recommendations 1.2.12, 1.2.13 and 1.2.16] 
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Quality statement 2 (developmental): Testing for 
advanced liver fibrosis 
Developmental quality statements set out an emergent area of cutting-edge service delivery or 
technology currently found in a minority of providers and indicating outstanding performance. 
They will need specific, significant changes to be put in place, such as redesign of services or new 
equipment. 
Quality statement 
People with non-alcoholic fatty liver disease are offered regular testing for advanced liver fibrosis. 
Rationale 
There is a risk that non-alcoholic fatty liver disease (NAFLD) will progress to fibrosis and then to 
cirrhosis. Regular testing for advanced liver fibrosis for people with NAFLD will enable those at 
high risk of disease progression to be identified so that they can receive advice, treatment and 
regular monitoring. Regular testing will also reduce unnecessary referrals or further testing for 
people who are at low risk of disease progression. 
Young people and adults with NAFLD should be offered testing in primary care, and referred to a 
specialist in hepatology if advanced liver fibrosis is diagnosed. Children with NAFLD who are 
diagnosed with advanced liver fibrosis should already be supported by a paediatric specialist in 
hepatology in tertiary care. 
Quality measures 
Structure 
a) Evidence of local referral pathways to ensure that people with NAFLD are offered regular testing 
for advanced liver fibrosis. 
Data source: Local data collection, for example, service protocol. 
b) Evidence that GP practices and paediatric hepatology services have arrangements to offer 
regular testing for advanced liver fibrosis to people with NAFLD. 
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Data source: Local data collection, for example, service protocol. 
Process 
a) Proportion of people newly diagnosed with NAFLD who are tested for advanced liver fibrosis. 
Numerator – the number in the denominator who are tested for advanced liver fibrosis. 
Denominator – the number of people newly diagnosed with NAFLD. 
Data source: Local data collection, for example, audit of patient health records. 
b) Proportion of adults with NAFLD identified as having a low risk of advanced liver fibrosis (such as 
an enhanced liver fibrosis [ELF] score below 10.51) who were tested for advanced liver fibrosis 
within the past 3 years. 
Numerator – the number in the denominator who were tested for advanced liver fibrosis within the 
past 3 years. 
Denominator – the number of adults with NAFLD identified as having a low risk of advanced liver 
fibrosis (such as an ELF score below 10.51). 
Data source: Local data collection, for example, audit of patient health records. 
c) Proportion of children and young people with NAFLD identified as having a low risk of advanced 
liver fibrosis (such as an ELF score below 10.51) who were tested for advanced liver fibrosis within 
the past 2 years. 
Numerator – the number in the denominator who were tested for advanced liver fibrosis within the 
past 2 years. 
Denominator – the number of children and young people with NAFLD identified as having a low 
risk of advanced liver fibrosis (such as an ELF score below 10.51). 
Data source: Local data collection, for example, audit of patient health records. 
Outcome 
a) Inappropriate referrals to a specialist for young people and adults with NAFLD. 
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Data source: Local data collection, for example, audit of patient health records. 
b) Incidence of advanced liver fibrosis in people with NAFLD. 
Data source: Local data collection, for example, audit of patient health records. 
What the quality statement means for different 
audiences 
Service providers (such as general practices and tertiary paediatric hepatology services) ensure 
that processes are in place to offer regular testing for advanced liver fibrosis to people with 
NAFLD. They should ensure that young people and adults diagnosed with advanced liver fibrosis 
are referred to a specialist in hepatology, and that children diagnosed with advanced liver fibrosis 
are cared for by a tertiary paediatric hepatology service. 
Healthcare professionals (such as GPs and paediatric hepatologists) offer regular testing for 
advanced liver fibrosis to people with NAFLD. GPs refer young people and adults diagnosed with 
advanced liver fibrosis to a specialist in hepatology. Paediatric hepatologists continue to care for 
children diagnosed with advanced liver fibrosis. 
Commissioners (such as clinical commissioning groups and NHS England) commission testing for 
advanced liver fibrosis for people with NAFLD. Commissioners ensure that providers offer testing 
and re-testing for advanced liver fibrosis to young people and adults with NAFLD and that there is 
sufficient capacity in hepatology services to meet expected demand for referrals for people 
diagnosed with advanced liver fibrosis. Commissioners ensure that tertiary paediatric hepatology 
services have capacity to support children diagnosed with advanced liver fibrosis. 
People withnon-alcoholic fatty liver disease have a test to check if their liver is scarred every 
3 years, or every 2 years if they are aged under 18. If the test shows that their liver is scarred, they 
are referred to a specialist in hepatology for further advice, treatment and check-ups, or cared for 
by a paediatric specialist in hepatology if they are under 16. 
Source guidance 
Non-alcoholic fatty liver disease (NAFLD): assessment and management. NICE guideline NG49 
(2016), recommendations 1.2.1 and 1.2.7 
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Definitions of terms used in this quality statement 
Regular testing for advanced liver fibrosis 
Testing for advanced liver fibrosis, for example with the enhanced liver fibrosis (ELF) test, should be 
offered to adults every 3 years and to children and young people every 2 years. [NICE's guideline on 
non-alcoholic fatty liver disease, recommendations 1.2.2, 1.2.7 and 1.2.8] 
Advanced liver fibrosis 
A grade of F3 or above using the Kleiner (NASH-CRN) or the steatosis, activity and fibrosis (SAF) 
score. This is referred to as bridging fibrosis (the presence of fibrosis linking hepatic veins to portal 
tracts). [NICE's guideline on non-alcoholic fatty liver disease] 
Children, young people and adults 
Children are aged under 16. Young people are aged 16 and 17. Adults are aged over 18. [NICE's 
guideline on non-alcoholic fatty liver disease] 
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Quality statement 3 (developmental): Non-
invasive testing for cirrhosis 
Developmental quality statements set out an emergent area of cutting-edge service delivery or 
technology currently found in a minority of providers and indicating outstanding performance. 
They will need specific, significant changes to be put in place, such as redesign of services or new 
equipment. 
Quality statement 
Young people and adults with risk factors for cirrhosis are offered non-invasive testing for cirrhosis. 
Rationale 
Cirrhosis may cause few or no symptoms and may not be identified until serious complications 
arise. Young people and adults with risk factors for cirrhosis should therefore be tested to find out 
if they have cirrhosis. Diagnosing cirrhosis will ensure that they get the treatment and support they 
need to manage their condition. Non-invasive testing is more acceptable to people than a liver 
biopsy and can be done in an outpatient setting with the results available immediately. 
Quality measures 
Structure 
a) Evidence of local availability of non-invasive testing for cirrhosis. 
Data source: Local data collection, for example, service specification. 
b) Evidence of local arrangements to ensure that young people and adults with risk factors for 
cirrhosis are offered non-invasive testing for cirrhosis. 
Data source: Local data collection, for example, service protocol. 
Process 
a) Proportion of young people and adults who have been drinking alcohol in a harmful way for 
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several months (for measurement purposes this could be at least 3 months) who receive 
non-invasive testing for cirrhosis. 
Numerator – the number in the denominator who receive non-invasive testing for cirrhosis. 
Denominator – the number of young people and adults who have been drinking alcohol in a harmful 
way for several months (for measurement purposes this could be at least 3 months). 
Data source: Local data collection, for example, audit of patient health records. 
b) Proportion of young people and adults diagnosed with hepatitis C virus infection who receive 
non-invasive testing for cirrhosis. 
Numerator – the number in the denominator who receive non-invasive testing for cirrhosis. 
Denominator – the number of young people and adults diagnosed with hepatitis C virus infection. 
Data source: Local data collection, for example, audit of patient health records. 
c) Proportion of adults newly referred for assessment for hepatitis B virus infection who receive 
non-invasive testing for cirrhosis. 
Numerator – the number in the denominator who receive non-invasive testing for cirrhosis. 
Denominator – the number of adults newly referred for assessment for hepatitis B virus infection. 
Data source: Local data collection, for example, audit of patient health records. 
d) Proportion of young people and adults diagnosed with alcohol-related liver disease who receive 
non-invasive testing for cirrhosis. 
Numerator – the number in the denominator who receive non-invasive testing for cirrhosis. 
Denominator – the number of young people and adults diagnosed with alcohol-related liver 
disease. 
Data source: Local data collection, for example, audit of patient health records. 
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e) Proportion of young people and adults diagnosed with non-alcoholic fatty liver disease with 
advanced liver fibrosis who receive non-invasive testing for cirrhosis. 
Numerator – the number in the denominator who receive non-invasive testing for cirrhosis. 
Denominator – the number of young people and adults diagnosed with non-alcoholic fatty liver 
disease with advanced liver fibrosis. 
Data source: Local data collection, for example, audit of patient health records. 
Outcome 
Incidence of cirrhosis. 
Data source: Local data collection, for example, audit of patient health records. 
What the quality statement means for different 
audiences 
Service providers (such as general practices and hospitals) ensure that they offer non-invasive 
testing for cirrhosis to young people and adults with risk factors for cirrhosis and give them 
information about the accuracy, limitations and risks of the different tests for diagnosing cirrhosis. 
Healthcare professionals (such as GPs, gastroenterologists and hepatologists) offer non-invasive 
testing for cirrhosis to young people and adults with risk factors for cirrhosis, and discuss the 
accuracy, limitations and risks of the different tests for diagnosing cirrhosis with them. 
Commissioners (such as clinical commissioning groups and NHS England) commission non-invasive 
testing for cirrhosis and ensure that providers offer it to young people and adults with risk factors 
for cirrhosis. They also ensure that providers give young people and adults with risk factors for 
cirrhosis information about the accuracy, limitations and risks of the different tests for diagnosing 
cirrhosis. 
Young people and adults who have a risk of cirrhosis either because they drink alcohol in a harmful 
way, or they have hepatitis B or C, alcohol-related liver disease or non-alcoholic fatty liver disease 
with advanced fibrosis, are offered a scan to check for cirrhosis. If cirrhosis is found, they are 
offered advice and treatment. 
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• Cirrhosis in over 16s: assessment and management. NICE guideline NG50 (2016), 
recommendations 1.1.3 and 1.1.4 
• Hepatitis B (chronic): diagnosis and management. NICE guideline CG165 (2013), 
recommendation 1.3.3 
Definitions of terms used in this quality statement 
Young people and adults 
Young people are aged 16 and 17. Adults are aged over 18. [NICE's guideline on non-alcoholic fatty 
liver disease] 
Risk factors 
Young people and adults have risk factors for cirrhosis if they: 
• drink alcohol in a harmful way, defined as more than 50 units of alcohol per week for men and 
more than 35 units per week for women, and have done so for several months or 
• have hepatitis C virus infection or 
• have been newly referred for assessment for hepatitis B virus infection (adults only) or 
• have been diagnosed with alcohol-related liver disease or 
• have been diagnosed with non-alcoholic fatty liver disease with advanced liver fibrosis. 
[NICE's guideline on cirrhosis in over 16s, recommendations 1.1.3 and 1.1.4, and NICE's guideline 
on hepatitis B (chronic), recommendation 1.3.3] 
Non-invasive testing for cirrhosis 
Non-invasive testing for cirrhosis includes: 
• transient elastography (for all people with risk factors for cirrhosis) or 
• acoustic radiation force impulse imaging (for young people and adults with non-alcoholic fatty 
liver disease and advanced liver fibrosis). 
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[NICE's guideline on cirrhosis in over 16s, recommendations 1.1.3 and 1.1.4, and NICE's guideline 
on hepatitis B (chronic), recommendation 1.3.3] 
Equality and diversity considerations 
Community outreach services should support young people and adults with risk factors for 
cirrhosis who are homeless or who inject drugs to enable them to have non-invasive testing for 
cirrhosis. 
Prisons should ensure that prisoners who have risk factors for cirrhosis are offered non-invasive 
testing for cirrhosis. 
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Quality statement 4: Surveillance for 
hepatocellular carcinoma 
Quality statement 
Adults with cirrhosis are offered 6-monthly surveillance for hepatocellular carcinoma. 
Rationale 
Cirrhosis is a substantial risk factor for hepatocellular carcinoma. Hepatocellular carcinoma 
develops quickly and may be asymptomatic until it is advanced. Regular surveillance of adults with 
cirrhosis at 6-month intervals helps to ensure that it is detected early. Treatment can then begin 
promptly, which can improve the person's chances of survival. 
Quality measures 
Structure 
Evidence of local arrangements to ensure that adults with cirrhosis are offered 6-monthly 
surveillance for hepatocellular carcinoma. 
Data source: Local data collection, for example, service protocol. 
Process 
Proportion of adults with cirrhosis who received ultrasound surveillance for hepatocellular 
carcinoma within the past 6 months. 
Numerator – the number in the denominator who received ultrasound surveillance for 
hepatocellular carcinoma within the past 6 months. 
Denominator – the number of adults with cirrhosis. 
Data source: Local data collection, for example, audit of patient health records. 
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a) Proportion of adults with cirrhosis who are diagnosed with hepatocellular carcinoma at an early 
stage. 
Numerator – the number in the denominator who are diagnosed with hepatocellular carcinoma at 
an early stage. 
Denominator – the number of adults with cirrhosis who are diagnosed with hepatocellular 
carcinoma. 
Data source:National Cancer Registration and Analysis Service cancer outcomes and services 
dataset. Early-stage diagnosis may be based, for example, on stages 0 or A of the Barcelona Clinic 
Liver Staging classification. 
b) Hepatocellular carcinoma survival rates. 
Data source: Local data collection, for example, audit of patient health records. Hepatocellular 
carcinoma is included within liver cancer in the Office for National Statistics' cancer survival for 
adults in England. 
What the quality statement means for different 
audiences 
Service providers (such as hospitals, and specialist liver centres) have recall systems in place to 
ensure that adults with cirrhosis are offered 6-monthly surveillance for hepatocellular carcinoma. 
Healthcare professionals (such as gastroenterologists and hepatologists) ensure that adults with 
cirrhosis are routinely offered 6-monthly surveillance for hepatocellular carcinoma. 
Commissioners (such as clinical commissioning groups) commission services that have recall 
systems in place to offer 6-monthly surveillance for hepatocellular carcinoma to adults with 
cirrhosis. 
Adults with cirrhosis should have a check for liver cancer every 6 months. This will ensure that they 
can be offered treatment as early as possible if liver cancer develops. 
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• Cirrhosis in over 16s: assessment and management. NICE guideline NG50 (2016), 
recommendation 1.2.4 
• Hepatitis B (chronic): diagnosis and management. NICE guideline CG165 (2013), 
recommendation 1.7.1 
Definitions of terms used in this quality statement 
Adults with cirrhosis 
Adults aged over 18 diagnosed with cirrhosis, excluding people who are receiving end of life care. 
[NICE's guideline on cirrhosis in over 16s, recommendations 1.2.4 and 1.2.6] 
6-monthly surveillance for hepatocellular carcinoma 
Ultrasound surveillance with or without measurement of serum alpha-fetoprotein. Surveillance for 
adults with cirrhosis who have hepatitis B should include alpha-fetoprotein testing. [NICE's 
guideline on cirrhosis in over 16s, recommendation 1.2.4, and NICE's guideline on hepatitis B 
(chronic), recommendation 1.7.1] 
Equality and diversity considerations 
Adults with cirrhosis who are homeless or who inject drugs may need additional support from 
community outreach services to ensure that they attend for 6-monthly surveillance for 
hepatocellular carcinoma. 
Prisons should ensure that prisoners with cirrhosis are offered 6-monthly surveillance for 
hepatocellular carcinoma. 
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Quality statement 5: Prophylactic intravenous 
antibiotics for upper gastrointestinal bleeding 
Quality statement 
Young people and adults with cirrhosis and upper gastrointestinal bleeding are given prophylactic 
intravenous antibiotics at presentation. 
Rationale 
People with cirrhosis and upper gastrointestinal bleeding are prone to have bacterial infections 
during or soon after a bleeding episode. Those who develop bacterial infections have a higher risk 
of death and early rebleeding. Giving prophylactic intravenous antibiotics at presentation reduces 
bacterial infections. Giving antibiotics intravenously also overcomes the difficulties of oral 
administration in people with haematemesis and critical illness. 
Quality measures 
Structure 
Evidence of local arrangements to ensure that young people and adults with cirrhosis and upper 
gastrointestinal bleeding are given prophylactic intravenous antibiotics at presentation. 
Data source: Local data collection, for example, service protocol. 
Process 
Proportion of presentations of young people and adults with cirrhosis and upper gastrointestinal 
bleeding in which the person receives prophylactic intravenous antibiotics at presentation. 
Numerator – the number in the denominator in which the person receives prophylactic intravenous 
antibiotics at presentation. 
Denominator – the number of presentations of young people and adults with cirrhosis and upper 
gastrointestinal bleeding. 
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Data source: Local data collection, for example, audit of patient health records. 
Outcome 
a) Rate of bacterial infection in young people and adults with cirrhosis and upper gastrointestinal 
bleeding. 
Data source: Local data collection, for example, audit of patient health records. 
b) Length of hospital stay for young people and adults with cirrhosis and upper gastrointestinal 
bleeding. 
Data source: Local data collection, for example, audit of patient health records. 
c) Hospital re-admission rate for young people and adults with cirrhosis and upper gastrointestinal 
bleeding. 
Data source: Local data collection, for example, audit of patient health records. 
d) Mortality rate in young people and adults with cirrhosis and upper gastrointestinal bleeding. 
Data source: Local data collection, for example, audit of patient health records. 
What the quality statement means for different 
audiences 
Service providers (such as hospitals, including emergency departments and specialist liver centres) 
have processes in place to ensure that young people and adults with cirrhosis and upper 
gastrointestinal bleeding are given prophylactic intravenous antibiotics at presentation. Providers 
should ensure that the choice of antibiotics is determined by local microbiological practices and 
that intravenous antibiotics are reviewed in line with NICE's guideline on antimicrobial 
stewardship. 
Healthcare professionals (such as emergency consultants, gastroenterologists and hepatologists) 
give prophylactic intravenous antibiotics to young people and adults with cirrhosis and upper 
gastrointestinal bleeding at presentation. Healthcare professionals ensure that the choice of 
antibiotics is determined by local microbiological practices and that intravenous antibiotics are 
reviewed in line with NICE's guideline on antimicrobial stewardship. 
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Commissioners (such as clinical commissioning groups) commission services that give prophylactic 
intravenous antibiotics to young people and adults with cirrhosis and upper gastrointestinal 
bleeding at presentation. 
Young people and adults with cirrhosis who are vomiting blood or passing blood in their stools
should be given antibiotics through a drip to stop them getting an infection. 
Source guidance 
Cirrhosis in over 16s: assessment and management. NICE guideline NG50 (2016), recommendation 
1.3.2 
Definitions of terms used in this quality statement 
Young people and adults 
Young people are aged 16 and 17. Adults are aged over 18. [NICE's guideline on non-alcoholic fatty 
liver disease] 
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About this quality standard 
NICE quality standards describe high-priority areas for quality improvement in a defined care or 
service area. Each standard consists of a prioritised set of specific, concise and measurable 
statements. NICE quality standards draw on existing NICE or NICE-accredited guidance that 
provides an underpinning, comprehensive set of recommendations, and are designed to support 
the measurement of improvement. 
Expected levels of achievement for quality measures are not specified. Quality standards are 
intended to drive up the quality of care, and so achievement levels of 100% should be aspired to (or 
0% if the quality statement states that something should not be done). However, this may not 
always be appropriate in practice. Taking account of safety, shared decision-making, choice and 
professional judgement, desired levels of achievement should be defined locally. 
Information about how NICE quality standards are developed is available from the NICE website. 
See our webpage on quality standard advisory committees for details of standing committee 2 
members who advised on this quality standard. Information about the topic experts invited to join 
the standing members is available from the webpage for this quality standard. 
This quality standard has been incorporated into the NICE Pathways on non-alcoholic fatty liver 
disease, cirrhosis and hepatitis B (chronic), which bring together everything we have said on a topic 
in an interactive flowchart. 
NICE has produced a quality standard service improvement template to help providers make an 
initial assessment of their service compared with a selection of quality statements. This tool is 
updated monthly to include new quality standards. 
NICE produces guidance, standards and information on commissioning and providing high-quality 
healthcare, social care, and public health services. We have agreements to provide certain NICE 
services to Wales, Scotland and Northern Ireland. Decisions on how NICE guidance and other 
products apply in those countries are made by ministers in the Welsh government, Scottish 
government, and Northern Ireland Executive. NICE guidance or other products may include 
references to organisations or people responsible for commissioning or providing care that may be 
relevant only to England. 
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This quality standard is expected to contribute to improvements in the following outcomes: 
• diagnosis of liver disease 
• progression of liver disease 
• detection of hepatocellular carcinoma 
• health-related quality of life for people with liver disease 
• hospital admissions for people with liver disease 
• length of hospital stay for people with liver disease 
• hospital re-admission rates for people with liver disease 
• mortality associated with liver disease. 
It is also expected to support delivery of the Department of Health's outcome frameworks: 
• Adult social care outcomes framework 
• NHS outcomes framework 
• Public health outcomes framework for England 
• Quality framework for public health. 
Resource impact 
NICE quality standards should be achievable by local services. The potential resource impact is 
considered by the quality standards advisory committee, drawing on resource impact work for the 
source guidance. Organisations are encouraged to use the resource impact products for the source 
guidance to help estimate local costs: 
• resource impact template for the NICE guideline on non\u2011\alcoholic fatty liver disease 
• resource impact template for the NICE guideline on cirrhosis 
• costing template for the NICE guideline on hepatitis B. 
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Diversity, equality and language 
During the development of this quality standard, equality issues were considered and equality 
assessments for this quality standard are available. Any specific issues identified during 
development of the quality statements are highlighted in each statement. 
Commissioners and providers should aim to achieve the quality standard in their local context, in 
light of their duties to have due regard to the need to eliminate unlawful discrimination, advance 
equality of opportunity and foster good relations. Nothing in this quality standard should be 
interpreted in a way that would be inconsistent with compliance with those duties. 
ISBN: 978-1-4731-2537-7 
Endorsing organisation 
This quality standard has been endorsed by NHS England, as required by the Health and Social 
Care Act (2012) 
Supporting organisations 
Many organisations share NICE's commitment to quality improvement using evidence-based 
guidance. The following supporting organisations have recognised the benefit of the quality 
standard in improving care for patients, carers, service users and members of the public. They have 
agreed to work with NICE to ensure that those commissioning or providing services are made 
aware of and encouraged to use the quality standard. 
• British Association for the Study of the Liver 
• Foundation for Liver Research 
• Primary Care Society for Gastroenterology 
• Royal College of Pathologists 
• Royal College of General Practitioners (RCGP) 
• British Liver Trust 
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